PE-backed I-Mab recruits Zhu as CFO
Shanghai-based I-Mab Biopharma, which focuses on biologics in therapeutic areas of immuno-oncology and immuno-inflammation, has appointed Jielun Zhu as chief financial officer. Previously, Zhu was managing director and Asia head of healthcare investment banking and capital markets in Hong Kong for Jefferies Group LLC. I-Mab is backed by Hony Capital, Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, EDBI, C-Bridge Capital and Tasly Capital.
1 August 2018•3 mins read
